HEADER TRANSFERASE/TRANSFERASE INHIBITOR 22-MAY-14 4QG7 TITLE S.AUREUS TMK IN COMPLEX WITH A POTENT INHIBITOR COMPOUND 18, 2-(3- TITLE 2 CHLOROPHENOXY)-3-METHOXY-4-{[(3S)-3-(5-METHYL-2,4-DIOXO-3,4- TITLE 3 DIHYDROPYRIMIDIN-1(2H)-YL)PIPERIDIN-1-YL]METHYL}BENZOIC ACID COMPND MOL_ID: 1; COMPND 2 MOLECULE: THYMIDYLATE KINASE; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: DTMP KINASE; COMPND 5 EC: 2.7.4.9; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: STAPHYLOCOCCUS AUREUS SUBSP. AUREUS; SOURCE 3 ORGANISM_TAXID: 282458; SOURCE 4 STRAIN: MRSA252; SOURCE 5 GENE: SAR0483, TMK; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL-21 (DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET28A KEYWDS TRANSFERASE/TRANSFERASE INHIBITOR KINASE, THYMIDINE MONPHOSPHATE, KEYWDS 2 TRANSFERASE-TRANSFERASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR N.B.OLIVIER REVDAT 4 03-APR-24 4QG7 1 REMARK REVDAT 3 28-FEB-24 4QG7 1 REMARK REVDAT 2 02-JUL-14 4QG7 1 JRNL REVDAT 1 11-JUN-14 4QG7 0 JRNL AUTH S.P.KAWATKAR,T.A.KEATING,N.B.OLIVIER,J.N.BREEN,O.M.GREEN, JRNL AUTH 2 S.Y.GULER,M.F.HENTEMANN,J.T.LOCH,A.R.MCKENZIE,J.V.NEWMAN, JRNL AUTH 3 L.G.OTTERSON,G.MARTINEZ-BOTELLA JRNL TITL ANTIBACTERIAL INHIBITORS OF GRAM-POSITIVE THYMIDYLATE JRNL TITL 2 KINASE: STRUCTURE-ACTIVITY RELATIONSHIPS AND CHIRAL JRNL TITL 3 PREFERENCE OF A NEW HYDROPHOBIC BINDING REGION. JRNL REF J.MED.CHEM. V. 57 4584 2014 JRNL REFN ISSN 0022-2623 JRNL PMID 24828090 JRNL DOI 10.1021/JM500463C REMARK 2 REMARK 2 RESOLUTION. 1.67 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER-TNT BUSTER 2.11.5 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.67 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 45.22 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 89.7 REMARK 3 NUMBER OF REFLECTIONS : 40294 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.189 REMARK 3 R VALUE (WORKING SET) : 0.187 REMARK 3 FREE R VALUE : 0.213 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 2014 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.67 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.71 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 89.72 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 1287 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2514 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1215 REMARK 3 BIN R VALUE (WORKING SET) : 0.2483 REMARK 3 BIN FREE R VALUE : 0.3004 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.59 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 72 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3104 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 70 REMARK 3 SOLVENT ATOMS : 236 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 21.70 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 27.08 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -2.20320 REMARK 3 B22 (A**2) : 6.43260 REMARK 3 B33 (A**2) : -4.22940 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -10.00860 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.205 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : NULL REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : NULL REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.116 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : NULL REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.925 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.916 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 3227 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 4368 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1136 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 88 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 480 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 3227 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 425 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 4090 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.00 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.23 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 16.61 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4QG7 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 23-MAY-14. REMARK 100 THE DEPOSITION ID IS D_1000086014. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 17-AUG-10 REMARK 200 TEMPERATURE (KELVIN) : 140 REMARK 200 PH : 7-8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU FR-E+ SUPERBRIGHT REMARK 200 MONOCHROMATIC OR LAUE (M/L) : NULL REMARK 200 WAVELENGTH OR RANGE (A) : 1.54 REMARK 200 MONOCHROMATOR : MIRROR REMARK 200 OPTICS : MONOCHROME REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RIGAKU SATURN 944+ REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : SCALA 3.3.15 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 40350 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.670 REMARK 200 RESOLUTION RANGE LOW (A) : 90.450 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 89.8 REMARK 200 DATA REDUNDANCY : 2.800 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.04000 REMARK 200 FOR THE DATA SET : 14.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.67 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.76 REMARK 200 COMPLETENESS FOR SHELL (%) : 47.0 REMARK 200 DATA REDUNDANCY IN SHELL : 1.70 REMARK 200 R MERGE FOR SHELL (I) : 0.34900 REMARK 200 R SYM FOR SHELL (I) : 0.34900 REMARK 200 FOR SHELL : 2.300 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: IN-HOUSE APOSTATE REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 41.41 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.10 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: TO OBTAIN THE INHIBITOR BOUND CRYSTAL REMARK 280 FORM OF TMK-S.AUREUS CRYSTALS WERE INITIALLY GROWN IN THE REMARK 280 ABSENCE OF COMPOUND USING THE SITTING DROP METHOD AT 293 K WITH REMARK 280 A RESERVOIR SOLUTION OF 100 MM PCPT (PROPIONATE-CACODYLATE- REMARK 280 BISTRIS PROPANE BUFFER) PH 7-8, 21-24% PEG 3350, 200 MM MG2CL REMARK 280 USING 1:1 PROTEIN:RESERVOIR SOLUTION WITH THE PROTEIN SOLUTION REMARK 280 AT 13 MG/ML. CRYSTALS WERE HARVESTED AND SOAKED OVERNIGHT IN A REMARK 280 SOLUTION CONTAINING 100 MM PCPT, 35% PEG 3350, 200 MM MG2CL AND REMARK 280 1-2 MM OR COMPOUND FROM A 100 MM DMSO STOCK. AFTER SOAKING THE REMARK 280 CRYSTALS WERE CRYOPROTECTED BY SOAKING FOR 15 MINUTES IN REMARK 280 COMPOUND-SOAK SOLUTION SUPPLEMENTED WITH 20% ETHYLENE GLYCOL., REMARK 280 VAPOR DIFFUSION, SITTING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 45.22500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2000 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 17700 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -19.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 SER A 146 REMARK 465 ARG A 147 REMARK 465 ASP A 148 REMARK 465 GLN A 149 REMARK 465 ASN A 150 REMARK 465 ARG A 151 REMARK 465 LEU A 152 REMARK 465 MET B 1 REMARK 465 ARG B 147 REMARK 465 ASP B 148 REMARK 465 GLN B 149 REMARK 465 ASN B 150 REMARK 465 ARG B 151 REMARK 465 LEU B 152 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ASP A 56 CG OD1 OD2 REMARK 470 LYS A 144 CE NZ REMARK 470 ASN A 145 CG OD1 ND2 REMARK 470 HIS A 172 CG ND1 CD2 CE1 NE2 REMARK 470 ASN A 173 CG OD1 ND2 REMARK 470 GLU A 174 CD OE1 OE2 REMARK 470 GLN A 176 CG CD OE1 NE2 REMARK 470 LYS A 204 CG CD CE NZ REMARK 470 LYS B 28 CE NZ REMARK 470 ASN B 55 CG OD1 ND2 REMARK 470 ILE B 143 CG1 CG2 CD1 REMARK 470 LYS B 144 CG CD CE NZ REMARK 470 ASN B 145 CG OD1 ND2 REMARK 470 GLU B 155 CG CD OE1 OE2 REMARK 470 LYS B 158 CD CE NZ REMARK 470 GLN B 168 CD OE1 NE2 REMARK 470 GLN B 176 CG CD OE1 NE2 REMARK 470 LYS B 179 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 MET B 34 SD MET B 34 CE -0.346 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 77 -52.95 -121.74 REMARK 500 ARG A 92 135.13 78.30 REMARK 500 TYR A 93 -144.70 -150.48 REMARK 500 GLN A 176 -64.79 -122.63 REMARK 500 LYS B 77 -53.76 -120.09 REMARK 500 ARG B 92 132.23 77.89 REMARK 500 TYR B 93 -144.11 -149.29 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 32K A 301 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 32K B 301 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4QGA RELATED DB: PDB REMARK 900 RELATED ID: 4QGF RELATED DB: PDB REMARK 900 RELATED ID: 4QGG RELATED DB: PDB REMARK 900 RELATED ID: 4QGH RELATED DB: PDB DBREF 4QG7 A 1 205 UNP Q6GJI9 KTHY_STAAR 1 205 DBREF 4QG7 B 1 205 UNP Q6GJI9 KTHY_STAAR 1 205 SEQRES 1 A 205 MET SER ALA PHE ILE THR PHE GLU GLY PRO GLU GLY SER SEQRES 2 A 205 GLY LYS THR THR VAL ILE ASN GLU VAL TYR HIS ARG LEU SEQRES 3 A 205 VAL LYS ASP TYR ASP VAL ILE MET THR ARG GLU PRO GLY SEQRES 4 A 205 GLY VAL PRO THR GLY GLU GLU ILE ARG LYS ILE VAL LEU SEQRES 5 A 205 GLU GLY ASN ASP MET ASP ILE ARG THR GLU ALA MET LEU SEQRES 6 A 205 PHE ALA ALA SER ARG ARG GLU HIS LEU VAL LEU LYS VAL SEQRES 7 A 205 ILE PRO ALA LEU LYS GLU GLY LYS VAL VAL LEU CYS ASP SEQRES 8 A 205 ARG TYR ILE ASP SER SER LEU ALA TYR GLN GLY TYR ALA SEQRES 9 A 205 ARG GLY ILE GLY VAL GLU GLU VAL ARG ALA LEU ASN GLU SEQRES 10 A 205 PHE ALA ILE ASN GLY LEU TYR PRO ASP LEU THR ILE TYR SEQRES 11 A 205 LEU ASN VAL SER ALA GLU VAL GLY ARG GLU ARG ILE ILE SEQRES 12 A 205 LYS ASN SER ARG ASP GLN ASN ARG LEU ASP GLN GLU ASP SEQRES 13 A 205 LEU LYS PHE HIS GLU LYS VAL ILE GLU GLY TYR GLN GLU SEQRES 14 A 205 ILE ILE HIS ASN GLU SER GLN ARG PHE LYS SER VAL ASN SEQRES 15 A 205 ALA ASP GLN PRO LEU GLU ASN VAL VAL GLU ASP THR TYR SEQRES 16 A 205 GLN THR ILE ILE LYS TYR LEU GLU LYS ILE SEQRES 1 B 205 MET SER ALA PHE ILE THR PHE GLU GLY PRO GLU GLY SER SEQRES 2 B 205 GLY LYS THR THR VAL ILE ASN GLU VAL TYR HIS ARG LEU SEQRES 3 B 205 VAL LYS ASP TYR ASP VAL ILE MET THR ARG GLU PRO GLY SEQRES 4 B 205 GLY VAL PRO THR GLY GLU GLU ILE ARG LYS ILE VAL LEU SEQRES 5 B 205 GLU GLY ASN ASP MET ASP ILE ARG THR GLU ALA MET LEU SEQRES 6 B 205 PHE ALA ALA SER ARG ARG GLU HIS LEU VAL LEU LYS VAL SEQRES 7 B 205 ILE PRO ALA LEU LYS GLU GLY LYS VAL VAL LEU CYS ASP SEQRES 8 B 205 ARG TYR ILE ASP SER SER LEU ALA TYR GLN GLY TYR ALA SEQRES 9 B 205 ARG GLY ILE GLY VAL GLU GLU VAL ARG ALA LEU ASN GLU SEQRES 10 B 205 PHE ALA ILE ASN GLY LEU TYR PRO ASP LEU THR ILE TYR SEQRES 11 B 205 LEU ASN VAL SER ALA GLU VAL GLY ARG GLU ARG ILE ILE SEQRES 12 B 205 LYS ASN SER ARG ASP GLN ASN ARG LEU ASP GLN GLU ASP SEQRES 13 B 205 LEU LYS PHE HIS GLU LYS VAL ILE GLU GLY TYR GLN GLU SEQRES 14 B 205 ILE ILE HIS ASN GLU SER GLN ARG PHE LYS SER VAL ASN SEQRES 15 B 205 ALA ASP GLN PRO LEU GLU ASN VAL VAL GLU ASP THR TYR SEQRES 16 B 205 GLN THR ILE ILE LYS TYR LEU GLU LYS ILE HET 32K A 301 35 HET 32K B 301 35 HETNAM 32K 2-(3-CHLOROPHENOXY)-3-METHOXY-4-{[(3S)-3-(5-METHYL-2,4- HETNAM 2 32K DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)PIPERIDIN-1- HETNAM 3 32K YL]METHYL}BENZOIC ACID FORMUL 3 32K 2(C25 H26 CL N3 O6) FORMUL 5 HOH *236(H2 O) HELIX 1 1 GLY A 14 VAL A 27 1 14 HELIX 2 2 VAL A 41 GLU A 53 1 13 HELIX 3 3 ASP A 58 LYS A 77 1 20 HELIX 4 4 LYS A 77 GLU A 84 1 8 HELIX 5 5 TYR A 93 GLN A 101 1 9 HELIX 6 6 GLY A 108 ASN A 121 1 14 HELIX 7 7 SER A 134 ASN A 145 1 12 HELIX 8 8 GLN A 154 GLU A 174 1 21 HELIX 9 9 PRO A 186 GLU A 203 1 18 HELIX 10 10 GLY B 14 VAL B 27 1 14 HELIX 11 11 VAL B 41 GLU B 53 1 13 HELIX 12 12 ASP B 58 LYS B 77 1 20 HELIX 13 13 LYS B 77 GLU B 84 1 8 HELIX 14 14 TYR B 93 GLN B 101 1 9 HELIX 15 15 GLY B 108 ASN B 121 1 14 HELIX 16 16 SER B 134 SER B 146 1 13 HELIX 17 17 GLN B 154 GLU B 174 1 21 HELIX 18 18 PRO B 186 GLU B 203 1 18 SHEET 1 A 5 VAL A 32 ARG A 36 0 SHEET 2 A 5 VAL A 87 ASP A 91 1 O LEU A 89 N ILE A 33 SHEET 3 A 5 ALA A 3 GLU A 8 1 N ALA A 3 O VAL A 88 SHEET 4 A 5 LEU A 127 ASN A 132 1 O LEU A 131 N GLU A 8 SHEET 5 A 5 PHE A 178 ASN A 182 1 O VAL A 181 N TYR A 130 SHEET 1 B 5 VAL B 32 ARG B 36 0 SHEET 2 B 5 VAL B 87 ASP B 91 1 O LEU B 89 N ILE B 33 SHEET 3 B 5 ALA B 3 GLU B 8 1 N ALA B 3 O VAL B 88 SHEET 4 B 5 LEU B 127 ASN B 132 1 O ILE B 129 N GLU B 8 SHEET 5 B 5 PHE B 178 ASN B 182 1 O VAL B 181 N TYR B 130 CISPEP 1 GLU A 37 PRO A 38 0 -2.37 CISPEP 2 GLU B 37 PRO B 38 0 -6.18 SITE 1 AC1 15 GLU A 37 ARG A 48 LEU A 52 PHE A 66 SITE 2 AC1 15 SER A 69 ARG A 70 ARG A 92 SER A 97 SITE 3 AC1 15 TYR A 100 GLN A 101 HOH A 428 HOH A 514 SITE 4 AC1 15 HOH A 515 HIS B 172 SER B 175 SITE 1 AC2 13 GLU B 37 ARG B 48 VAL B 51 PHE B 66 SITE 2 AC2 13 SER B 69 ARG B 70 ARG B 92 SER B 97 SITE 3 AC2 13 TYR B 100 GLN B 101 HOH B 516 HOH B 517 SITE 4 AC2 13 HOH B 518 CRYST1 46.040 90.450 48.370 90.00 102.10 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.021720 0.000000 0.004656 0.00000 SCALE2 0.000000 0.011056 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021144 0.00000